key: cord-0995677-yxtkxbag
authors: Hussein, Heba; Brown, Ronald S.
title: Hydroxychloroquine and the treatment of Sjogren's Syndrome, Chronic Ulcerative Stomatitis, and Oral Lichen Planus in the age of COVID-19
date: 2020-06-20
journal: Oral Surg Oral Med Oral Pathol Oral Radiol
DOI: 10.1016/j.oooo.2020.06.011
sha: f7d76b26c39114d4a47a5bbfb20ad7440c4c0364
doc_id: 995677
cord_uid: yxtkxbag

The Federal Drug Administration has recently approved the off-label use of Hydroxychloroquine (HCQ) for the treatment of COVID-19 infections. However, a recent study has not only failed to demonstrate HCQ efficacy but has documented an HCQ COVID-19 therapy serious side-effect of QT prolongation and secondary arrhythmia. HCQ has been utilized as an off-label drug and deemed safe and effective for such oral lesions as Sjogren's syndrome (SS), Chronic Ulcerative Stomatitis (CUS), and Oral Lichen Planus (OLP). As HCQ may be appropriately utilized for the off-label treatment of SS, CUS, and OLP, the relevant HCQ safety concerns such as dosage, drug-drug interactions, and QT prolongation and secondary arrhythmia are discussed. Due to the possibility of decreased pharmacy HCQ supplies, replacement drugs with respect to SS, CUS, and OLP patients being successfully treated with HCQ are also discussed.

Stomatitis, and Oral Lichen Planus in the age of COVID -19 Hydroxychloroquine (HCQ) is a drug that is FDA-approved for the prevention and treatment of malaria for many years. 1 HCQ has been utilized as an off-label drug and deemed safe and effective for such oral conditions as Sjogren's syndrome (SS), Chronic Ulcerative Stomatitis (CUS), and Oral Lichen Planus (OLP). [2] [3] [4] [5] [6] [7] [8] Due to the belief that HCQ may could be viable as a Covid 19 therapeutic, the FDA has recently granted approval of HCQ for the treatment of Covid 19 infections. 9 However, the very recent publication of a study by Mehra et al., 10 has changed the landscape with respect to our understanding of the efficacy and safety of HCQ therapy for Covid 19 infection particularly with respect to increased mortality. Mehra et al., 10 reported the findings of a retrospective study of 96,032 subjects (mean age of 53.8 years, 46.3% women) hospitalized subjects with Covid-19. They reported that they were not able to determine any benefit of HCQ or chloroquine therapies either individually or when combined with azithromycin. Furthermore, they noted that these drug Covid -19 protocols were associated with decreased survival and an increased frequency of ventricular arrhythmias. With the understanding that HCQ therapy has a dose-related risk of lethal arrhythmia related to QT prolongation, dentists and particularly oral medicine specialists, should harbor a concern for potential interactions with drugs which are known to increase QT prolongation. 2,11-13 Tisdale et al, 14 reported that in 2013, as many as 28% of patients admitted to hospital cardiac care may present with QT cardiac (QTc) interval prolongation. However, some countries persist in using HCQ therapy for COVID-19 infections. 15 It has been noted that HCQ therapy is associated with a rare sudden death complication due to a particular cardiac arrhythmia related to QT prolongation. [10] [11] [12] [13] This side-effect appears to be dose-related. As other drugs are also known to cause QT prolongation, it is important for HCQ prescribing dentists to be aware of potential additive drug-drug interaction regarding drugs prescribed by both dentists and physicians. 2 Torsade de pointes (TdP) arrhythmia is associated with prolonged QT duration secondary to high dose HCQ administration and HCQ proarrhythmic toxicity appears to be dose related. [9] [10] [11] In 2006, Chen et al., 11 reported a case of a 67year-old female patient with acquired long QT duration a refractory arrhythmia. The patient was receiving HCQ for lupus therapy and developed TdP arrhythmia. After discontinuing HCQ, the QT interval became shorter and the patient recovered.

In 2016, O'Laughlin et al., 13 reported a case of HCQ -related QT interval prolongation and secondary arrhythmia TdP in a patient with renal failure. They concluded that HCQ-related torsade de pointes arrhythmia is relatively rare and may be related to higher HCQ dosage regimens. In 2018, McGhie et al, 16 reported regarding potential conduction abnormalities on electrocardiograms (ECGs) secondary to anti-malarial drug therapies. With respect to the treatment of 453 subjects, they reported approximately 16% with conduction disorders. They concluded an association between cumulative anti-malarial dose above a particular median dose and structural ECG abnormalities. On the other hand, Sharma et al. 17 evaluated 1,266 rheumatoid arthritis subjects with 547 subjects treated with HCQ and 719 subjects treated without HCQ and reported that HCQ therapy in rheumatoid arthritis patients resulted in a 72% decrease in the risk of cardiovascular disease incidents.

Long QT syndrome (LQTS) is a unique cardiovascular condition resulting in dysfunctional cardiac ion channels. Due to a long repolarization phase of the ventricle, there is a lengthening of the QT interval. Increased QT duration leads to progression to TdP and ventricular fibrillation and sudden death. Precipitating factors with respect to LQTS include emotional stress, load noise, physical activity, and certain medications which influence QT duration. 18 There are several issues related to HCQ and oral medicine: 1) What are the secondary drugs to consider as replacement drugs when your SS, CUS, and OLP patients successfully managed with HCQ are unable to fill their HCQ prescriptions due to decreased pharmacy supplies? Injectable steroid therapeutic drugs include triamcinolone and betamethasone. Other alternative therapeutics include topical retinoid therapy and low level laser therapy. [19] [20] [21] [22] [23] [24] [25] [26] [27] Factors Associated with increased risk of developing drug-induced excessive QT prolongation and/or TdP The major issue with respect to dental patients taking HCQ is drug-drug interactions with concern for arrhythmogenic potential and specifically the TdP arrhythmia which is potentially lethal. In 1997, the drug terenadine (a histamine one blocker non-sedating antihistamine) was taken off the market due to the causation of fatal arrhythmias in combination with other drugs and specifically with some drugs used by dentists such as ketoconazole and erythromycin. These dental drugs were thought to mainly cause competitive inhibition drug-drug interaction to slow down the 3A4 cytochrome P450 elimination pathway resulting in increased serum values of the problematic drug terfenadine. [28] [29] [30] In 2009 and 2016, Cubeddu 31,32 reviewed the mechanisms and clinical significance of druginduced QT abnormalities with lethal arrhythmias. His report included such drug categories as antibiotics, antiprotozoals, antifungals, anti-neoplastic, pro-kinetics, 5HT3-receptor antagonists, antihistamines, 5-HT1D agonists, anti-psychotics, antidepressants, opioids, and drugs with cardiac and vascular effects. Of these categories, antibiotics, antifungals, antidepressants, and opioids are utilized by dentists. Specific drugs utilized by dentists with documented drug-induced QT prolongation potential include erythromycin, clarithromycin, azithromycin, 33-35 ketoconazole, itrconazole, fluconazole, miconazole, posaconazole, voriconazole, desipramine, imipramine, doxepin, and methadone 34 Azithromycin is a unique macrolide antibiotic in that it doesn't have the problematic elimination pathway utilized by other macrolides which improves safety. 36 However, azithromycin has been demonstrated to be proarryhthmic similarly to other macrolides. 33-35 In a retrospective study, Choi et al., 34 reported that azithromycin utilization increased the risk of QT prolongation particularly with respect to the elderly.

Fiets et al., 37 evaluated QT prolongation with erythromycin and determined that erythromycin at a dose of 200 mg twice daily administration significantly prolonged QT duration. Ebert et al, 38 Drici et al, 39 Arya 40 reported that erythromycin and clarithromycin created a greater risk for women with respect to LQTS and women.

Erythromycin, clarithromycin, ketoconazole, miconazole, and itraconazole are all known to interfere in competitive inhibition of the cytochrome P450 -3A4 elimination pathway. These drugs when prescribed concomitantly with drugs which prolong the QT duration and share the same elimination pathway would tend to increase serum values of other drugs which prolong QT duration and therefore, increase the likelihood of TdP arrhythmia and death. [37] [38] [39] [40] Tett et al, 41 reported that the elimination half-life of HCQ was approximately 44 days after IV administration. McChesney et al., 42 reported that the elimination/detoxification pathway for HCQ followed degradation of HCQ into a secondary amine, either desethyl chloroquine, or desethyl hydroxychloroquine, or a primary amine, the 4'-aldehyde and lastly the 4'-carboxy derivative. It is noted HCQ is not eliminated through the cytochrome P450 -3A4 elimination pathway. 41, 42 Karp and Moss 43 reported concerning the dental treatment of patients with long QT syndrome.

However, the article did not mention HCQ. Furthermore, HCQ would not be recommended for patients with an existing diagnosis of prolonged QT duration, or patients with a history of syncope and/or seizures, or a family history of long QT syndrome, syncope, seizures, or sudden cardiac death.

Also, Karp and Moss 43 listed a number of other drugs which they noted were drugs used in dentistry that they associated with inducing QT prolongation that included several drugs not noted by Cubeddu such as dolasetron, droperidol, chloral hydrate, haloperidol, albuterol, amiodarone, epinephrine, ephedrine, metaproterenol, and cocaine. Chloral hydrate is not presently used, and there is certainly an argument with respect to epinephrine in local anesthesia utilization in patients with prolonged QT duration. The other drugs are not currently utilized in dentistry. Karp and Moss 43 referenced Ackerman et al. 44 who evaluated subjects with epinephrine infusions rather than inter-muscular injection which have considerably different kinetics. Furthermore, utilizing two to three cartridges of epinephrine local anesthetic formulations appears to be safe and effective for medically complex patients with cardiac disease. Physicians utilize an epinephrine concentration of 1:1,000 and are unfamiliar with the 1:100,000 concentration typically utilized in dentistry. Epinephrine definitely has beta one effects resulting in increased heart rate, however, it also is important with respect to pain control, and lack of pain control tends to result in increased endogenous production of norepinephrine which is more problematic with respect to both heart rate and blood pressure. 28, [45] [46] [47] [48] In 2006, Karp and Moss 43 defended their recommendations related to epinephrine risks with respect to Long QT syndrome by stating that "Epinephrine-containing local anesthetics have never been shown to be safe and effective for patients with LQTS." However, in 2007, Wynn 49 reported that articaine 4% with 1:200,000 epinephrine was judged to be safe and effective in dental patients with LQTS.

In 2009, Rochford and Seldin 18 reviewed the management of a dental patient with LQTS. They recommended a consultation with the patient's physician and every effort to reduce stress and anxiety.

The authors suggested that atropine should be avoided in dental patients with LQTS. They also discouraged the utilization of epinephrine within local anesthetic formulations for patients with LQTS (although there is disagreement on this issue). [45] [46] [47] [48] [49] With respect to the treatment for the TdP arrhythmia, Rochford and Seldin 18 advocated immediate IV bolus of Magnesium sulfate at 30 mg/kg over a 2 to 3 minute period, to be followed by an infusion of 2 to 4 mg of Magnesium sulfate per minute. They concluded that treating dental patients with LQTS requires understanding of the seriousness of LQTS and the elimination of precipitating factors which could elicit TdP arrhythmia.

They suggested considering treatment within a hospital environment.

Snitker et al., 50 defined QTc (QT interval corrected for heart rate) as prolonged when greater or equal to 450 milliseconds. They evaluated 3,252 Chronic Renal Insufficiency Cohort subjects with at least one study electrocardiogram. They evaluated QT-prolonging medications used in100 or more visits (n=16,451 visits) along with diuretics and proton pump inhibitors for QT interval prolongation.

Six drugs were shown to be associated with QTc prolongation as a continuous variable including fluoxetine, citalopram, escitalopram, venlafaxine, hydroxyzine and amiodarone. The same six drugs were associated with increased odds ratio of (QTc greater or equal to 450 milliseconds) except venlafaxine. Nortriptyline was associated with QTc shortening rather than prolongation but was not associated with a lower odds ratio of QTc greater or equal to 450 milliseconds. They evaluated such SSRIs as sertraline, fluoxetine, citalopram, paroxetine, and escitalopram. They evaluated other antidepressants as amitriptyline, trazodone, venlafaxine, nortriptyline, and mirtazapine. Central nervous system drugs they evaluated included hydroxyzine and Quetiapine. None of the proton pump inhibitor drugs demonstrated QT prolongation, and such other drugs as diphenhydramine, famotidine, metoclopramide, quinine, cilostazol, and tolterodine also were evaluated as negative for QT prolongation. Table #1 is provided to illustrate potential drug-drug interactions with HCQ and drugs utilized by oral medicine specialists in the treatment of oral conditions. Table #2 is provided to list drugs prescribed by physicians noted to increase the risk of TdP arrhythmia. To our knowledge, there are no known incidences HCQ-induced arrhythmias with respect to the treatment of oral autoimmune conditions. With respect to low dose HCQ prophylactic therapy for malaria, and HCQ therapy for rheumatoid conditions, the side-effect of HCQ-induced arrhythmia is a rare event. 51 We perceive that due to utilizing relatively low dosage regimens for the treatment of oral autoimmune conditions, secondary HCQ-related arrhythmia has been avoided. However, clinicians need to consider risk assessment regarding such potential QT prolongation with respect to HCQ administration and additive drug-drug interactions. Also, it is necessary for clinicians employing HCQ therapy to alert patients regarding the potential side-effect of conjunctivitis. 52, 53 Communication with patients' physicians is particularly helpful concerning requests for consideration for changes in prescription medications and ocular concerns. 54 In conclusion, it is noted that with the present decrease in the availability of hydroxychloroquine, it may be necessary to for treating dentists to consider alternative medications to replace hydroxychloroquine. Hydroxychloroquine is a relatively safe drug when used at appropriate therapeutic dosage levels for malaria prophylaxis and in the treatment rheumatologic conditions. However, at increased dosage levels and with drug-drug interactions with other drugs known for increased QT prolongation, its pro-arrhythmic toxicity may be enhanced. It is important for dentists to understand the toxicity of hydroxychloroquine with respect to the treatment of dental patients taking hydroxychloroquine.

References:

1. Plantone D, Koudriaviseya T. Current and future use of chloroquine and hydroxychloroquine in 

infectious, immune, neoplastic, and neurological diseases: A mini-review

off-label" utilization in the treatment of oral conditions. Oral Surg Oral Med Oral Pathol Oral Radiol

Chronic ulcerative stomatitis: Diagnostic and management challenges -four new cases and review literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod

Chronic ulcerative stomatitis: a distinct clinical entity?

Hydroxychloroquine sulphate therapy of erosive oral lichen planus

Effects of hydroxychloroquine on salivary flow rates and oral complaints of Sjogren patients: a prospective sample study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod

New Treatment guidelines for Sjogren's disease

Sweet's syndrome following therapy with Hydroxychloroquine in a patient with primary Sjogren's syndrome. Medicines (Basel)

FDA approves hydroxychloroquine new drug application to address COVID-19 related shortage

885d79ab94ca%7D/fda-approves-hydroxychloroquine-new-drug-application-to-address-covid-19-related-shortage

Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

Chronic hydroxychloroquine use associated with QT prolongation and refractory ventricular arrhythmia

Cardiac Complications Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the Literature

Life Threatening Severe QTc Prolongation in Patient with

Systemic Lupus Erythematosus due to Hydroxychloroquine

Development and validation of a risk score to predict QT interval prolongation in hospitalized patients

Hydroxychloroquine: Turkey insists on using drug despite WHO concerns

Electrocardiograph abnormalities related to anti-malarials in systemic lupus erythematosus

Hydroxychloroquine use is associated with decreased incident cardiovascular events in rheumatoid arthritis patients

Review and management of dental patient with long QT syndrome (LQTS) Anes Prog

Clinician's Guide to Treatment of Common Oral Conditions

Successful treatment of oral erosive lichen planus with mycophenolate mofetil

Painful Oral Lesions

Topical calcineurin inhibitors in the treatment of oral lichen planus: a systematic review and meta-analysis

Treatment of oral lichen planus. Systematic review and therapeutic guide

Topical immunomodulators for management of oral mucosal conditions, a systematic review; Part II: miscellaneous agents

Interventions for the management of oral lichen planus: a review of the conventional and novel therapies

Intralesional triamcinolone acetonide therapy for inflammatory oral ulcers. Oral Surg Oral Med Oral Pathol Oral Radiol

Efficacy of intralesional betamethasone for erosive oral lichen planus and evaluation of recurrence: a randomized, controlled trial. Oral Surg Oral Med Oral Pathol Oral Radiol

Dental drug interactions with the greatest potential for serious adverse effects

Cardiac actions of antihistamines

Antihistamine drug withdrawn by manufacturer

Iatrogenic QT Abnormalities and Fatal Arrhythmias: Mechanisms and Clinical Significance

Drug-induced Inhibition and Trafficking Disruption of ion Channels: Pathogenesis of QT Abnormalities and Drug-induced Fatal Arrhythmias

Azithromycin causes a novel proarrhythmic syndrome

Risk evaluation of azithromycin-induced QT prolongation in Real-World practice

Azithromycin-induced proarryhthmia and cardiovascular death

Pharmacokinetics and pharmacodynamics of intravenous and oral azithromycin: enhanced tissue

QTc prolongation during erythrmycin used as prokinetic agent in ICU patients

Female gender as a risk factor for drug-induced cardiac arrhythmias: evaluation of clinical and experimental evidence

Is gender a risk factor for adverse drug reactions? The example of druginduced long QT syndrome

Gender-related differences in ventricular repolarization: beyond gonadal steroids

A dose-ranging study of the pharmacokinetics of hydroxychloroquine following intravenous administration to healthy volunteers

Studies of the metabolism of some compounds of the 4-amino-7-chloroquinoline series

Dental treatment of patients with long QT syndrome

Epinephrine-induced QT interval prolongation: a gene specific paradoxical response in congenital long QT syndrome

Long QT syndrome

Dental management of the patients with cardiac arrhythmias: An update

Epinephrine and local anesthesia revisited. Oral Surg Oral Med Oral Pathol Oral Radiol Endod

The chicken little syndrome

Articaine 4% with 1:200,000 epinephrine: an acceptable option for patients with long QT syndrome

Association of QT prolonging medication use in CKD with electrocardiographic manifestations

Hydroxychloroquine: From malaria to autoimmunity

Ocular side effects of antirheumatic medications: what a rheumatologist should know

What is new in recommendations on ophthalmological screening in patients treated with chloroquine and hydroxychloroquine? Update and literature review

Medical consultations for medically complex dental patients

Anti-fungal